Corrigendum : Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (Front. Oncol., (2023), 13, 1223282, 10.3389/fonc.2023.1223282)
Buchler, T. (Thomayer University Hospital)
Grünwald, Viktor (University Hospital Essen (Alemanya))
Powles, Thomas (Queen Mary University of London)
Eto, Masatoshi (Kyushu University)
Kopyltsov, Evgeny (State Institution of Healthcare Regional Clinical Oncology Dispensary)
Rha, Sun Young (Yonsei University Health System)
Porta, Camillo (University of Bari 'A. Moro')
Motzer, Robert (Memorial Sloan Kettering Cancer Center)
Hutson, Thomas E. (Texas Oncology)
Méndez-Vidal, María José (Hospital Universitario Reina Sofía (Còrdova, Espanya))
Hong, Sung-Hoo (The Catholic University of Korea)
Winquist, Eric (University of Western Ontario)
Goh, Jeffrey C. (South Brisbane & University of Queensland)
Maroto Rey, Pablo (Institut de Recerca Sant Pau)
Takagi, Toshio (Tokyo Women's Medical University)
Burgents, Joseph (Global Clinical Development. Merck & Co.. Inc.)
Perini, Rodolfo (Clinical Research. Merck & Co.. Inc.)
He, Cixin (Biostatistics. Eisai Inc.)
Okpara, Chinyere E. (Clinical Research. Eisai Ltd)
McKenzie, Jodi (Clinical Research. Eisai Inc.)
Choueiri, Toni K. (Dana-Farber Cancer Institute)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2023
Resum:	In the published article, there was an error in the legend for Figure 3 and Supplementary Table 1 as published. Clarification that objective response rates and complete response rates were calculated based on the number of patients in each listed subgroup was omitted. The corrected legend of both appears below. ORR and Odds Ratios for Lenvatinib + Pembrolizumab Versus Sunitinib Treatment in Subgroups of Interest. As assessed by IRC per RECIST v1. 1. Percents were calculated based on listed subgroups. CI, confidence interval; CR, complete response; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; IRC, independent review committee; ITT, intention to treat; L+P, lenvatinib + pembrolizumab; MSKCC, Memorial Sloan Kettering Cancer Center; ORR, objective response rate; RECIST v1. 1, Response Evaluation Criteria In Solid Tumors version 1. 1; S, sunitinib. "As assessed by IRC per RECIST v1. 1. Percents were calculated based on listed subgroups. " In the published article, there was an error in Figure 3 and Supplementary Table 1 as published. For both, percentages in the "complete response" column were incorrectly calculated as the number of patients with a complete response in each subgroup divided by all patients in the respective treatment arm (n=355 for lenvatinib + pembrolizumab; n=357 for sunitinib) instead of being divided by the number of patients in each applicable subgroup. The corrected Figure 3 and its captions (also corrected per the above to "As assessed by IRC per RECIST v1. 1. Percents were calculated based on listed subgroups. ") appear below. The text did not account for the revisions made to the complete response rate mentioned above. A correction has been made to Section 3. 2. 3 (Objective response), paragraph 2. This sentence previously stated: "As expected, the rates of CRs were higher in patients without baseline bone metastases or baseline liver metastases, in patients who had baseline lung metastases, and in patients who had a prior nephrectomy. While the number of patients with sarcomatoid features was small, the rates of CRs in patients without sarcomatoid features was higher than those of patients with sarcomatoid features. " The corrected sentence appears below: "As expected, the rates of CRs were higher in patients without baseline bone metastases, and in patients who had a prior nephrectomy. CR rates were similar irrespective of whether or not patients had baseline liver metastases. " The Supplementary Table 1 has been updated directly in the original article. The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Bone metastases ; Lenvatinib ; Liver metastases ; Lung metastases ; Pembrolizumab ; Renal cell carcinoma ; Sarcomatoid histology ; Sunitinib
Publicat a:	Frontiers in Oncology, Vol. 13 (2023) , art. 1343027, ISSN 2234-943X

DOI: 10.3389/fonc.2023.1343027
PMID: 38495081

2 p, 1.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats